Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
Protagonist Therapeutics (NASDAQ:PTGX) has announced its participation in the BTIG Virtual Biotechnology Conference 2024. The event is scheduled for August 5-6, 2024. Dinesh V. Patel, Ph.D., the company's President and CEO, will take part in a fireside chat on Tuesday, August 6 from 2:00-2:35 P.M. EDT.
In addition to the fireside chat, Protagonist's team will be available for one-on-one meetings during the conference. Interested parties are encouraged to contact their BTIG representative to arrange meetings with the Protagonist team.
Protagonist Therapeutics (NASDAQ:PTGX) ha annunciato la sua partecipazione al BTIG Virtual Biotechnology Conference 2024. L'evento si svolgerà dal 5 al 6 agosto 2024. Dinesh V. Patel, Ph.D., Presidente e CEO dell'azienda, parteciperà a un incontro informale il martedì 6 agosto dalle 14:00 alle 14:35 EDT.
Oltre all'incontro informale, il team di Protagonist sarà disponibile per incontri individuali durante la conferenza. Le parti interessate sono invitate a contattare il proprio rappresentante BTIG per organizzare incontri con il team di Protagonist.
Protagonist Therapeutics (NASDAQ:PTGX) ha anunciado su participación en la Conferencia Virtual de Biotecnología BTIG 2024. El evento está programado para 5 y 6 de agosto de 2024. Dinesh V. Patel, Ph.D., presidente y CEO de la compañía, participará en una charla informal el martes 6 de agosto de 2:00 a 2:35 P.M. EDT.
Además de la charla, el equipo de Protagonist estará disponible para reuniones individuales durante la conferencia. Se anima a las partes interesadas a contactar a su representante de BTIG para organizar reuniones con el equipo de Protagonist.
Protagonist Therapeutics (NASDAQ:PTGX)은 BTIG 가상 생명공학 컨퍼런스 2024에 참여한다고 발표했습니다. 이 행사는 2024년 8월 5일부터 6일로 예정되어 있습니다. 회사의 회장 겸 CEO인 Dinesh V. Patel 박사가 8월 6일 화요일 오후 2시부터 2시 35분까지 EDT에 진행되는 파이어사이드 채팅에 참여합니다.
파이어사이드 채팅 외에도 Protagonist 팀은 컨퍼런스 동안 개별 미팅이 가능합니다. 관심 있는 분들은 Protagonist 팀과의 미팅을 주선하기 위해 BTIG 대표에게 연락해 주시기 바랍니다.
Protagonist Therapeutics (NASDAQ:PTGX) a annoncé sa participation à la Conférence Virtuelle de Biotechnologie BTIG 2024. L'événement est prévu pour les 5 et 6 août 2024. Dinesh V. Patel, Ph.D., président et PDG de l'entreprise, participera à une discussion informelle le mardi 6 août de 14h00 à 14h35 EDT.
En plus de la discussion, l'équipe de Protagonist sera disponible pour des rencontres individuelles durant la conférence. Les parties intéressées sont invitées à contacter leur représentant BTIG pour organiser des rencontres avec l'équipe de Protagonist.
Protagonist Therapeutics (NASDAQ:PTGX) hat seine Teilnahme an der BTIG Virtual Biotechnology Conference 2024 bekannt gegeben. Die Veranstaltung findet am 5. und 6. August 2024 statt. Dinesh V. Patel, Ph.D., Präsident und CEO des Unternehmens, wird am Dienstag, den 6. August von 14:00 bis 14:35 Uhr EDT an einem informellen Gespräch teilnehmen.
Zusätzlich zu dem informellen Gespräch wird das Team von Protagonist während der Konferenz für Einzelgespräche zur Verfügung stehen. Interessierte Parteien werden ermutigt, ihren BTIG-Vertreter zu kontaktieren, um Meetings mit dem Protagonist-Team zu vereinbaren.
- None.
- None.
NEWARK, CA / ACCESSWIRE / July 22, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the BTIG Virtual Biotechnology Conference.
BTIG Virtual Biotechnology Conference - August 5-6, 2024
Format: Fireside Chat
Day/Time: Tuesday, August 6 at 2:00-2:35 P.M. EDT
If you are interested in meeting with the Protagonist team during the conference, please reach out to your BTIG representative.
About Protagonist
Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities (NCEs) rusfertide and JNJ-2113 (formerly PN-235) in advanced Phase 3 stages of clinical development, both derived from the Company's proprietary technology platform. Protagonist and JNJ scientists jointly discovered PN-235 as part of Protagonist's Interleukin-23 receptor (IL-23R) antagonist collaboration with JNJ and followed it through IND-enabling pre-clinical and Phase 1 studies, with JNJ assuming responsibility for further clinical development. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 development program for polycythemia vera (PV). The randomized portion of the Phase 2 REVIVE study has been successfully completed, and results were published in The New England Journal of Medicine in February 2024. The open-label extension (OLE) component of Phase 2 REVIVE study is ongoing, followed by an additional 2-year long-term extension (LTE) THRIVE study. Enrollment has been completed in the global Phase 3 VERIFY study of rusfertide in polycythemia vera. Rusfertide is being co-developed and co-commercialized with Takeda pursuant to a worldwide collaboration and license agreement with Takeda announced in January 2024.
More information on Protagonist and its pipeline drug candidates and clinical studies can be found on the Company's website at www.protagonist-inc.com.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Media Contact
Virginia Amann, Founder/CEO
ENTENTE Network of Companies
virginiaamann@ententeinc.com
SOURCE: Protagonist Therapeutics, Inc.
View the original press release on accesswire.com
FAQ
When is Protagonist Therapeutics (PTGX) participating in the BTIG Virtual Biotechnology Conference 2024?
Who will represent Protagonist Therapeutics (PTGX) at the BTIG Virtual Biotechnology Conference 2024?
What type of presentation will Protagonist Therapeutics (PTGX) give at the BTIG Virtual Biotechnology Conference 2024?
How can investors arrange meetings with Protagonist Therapeutics (PTGX) during the BTIG Virtual Biotechnology Conference 2024?
